These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36913260)

  • 21. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
    Hovinga KE; McCrea HJ; Brennan C; Huse J; Zheng J; Esquenazi Y; Panageas KS; Tabar V
    J Neurooncol; 2019 Apr; 142(2):337-345. PubMed ID: 30680510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapy with anlotinib for patient with recurrent glioblastoma: A case report and literature review.
    Lv Y; Zhang J; Liu F; Song M; Hou Y; Liang N
    Medicine (Baltimore); 2019 May; 98(22):e15749. PubMed ID: 31145289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of almonertinib and anlotinib combination therapy for advanced non-small-cell lung cancer patients who continued to experience cancer progression during third-generation EGFR-TKI treatment: a retrospective study.
    Zhang Y; Wang C; Zhao J; Wang M
    Thorac Cancer; 2024 Jul; ():. PubMed ID: 38987909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
    Nam Y; Koo H; Yang Y; Shin S; Zhu Z; Kim D; Cho HJ; Mu Q; Choi SW; Sa JK; Seo YJ; Kim Y; Lee K; Oh JW; Kwon YJ; Park WY; Kong DS; Seol HJ; Lee JI; Park CK; Lee HW; Yoon Y; Wang J
    Genome Med; 2023 Mar; 15(1):16. PubMed ID: 36915208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma.
    Areeb Z; Stuart SF; West AJ; Gomez J; Nguyen HPT; Paradiso L; Zulkifli A; Jones J; Kaye AH; Morokoff AP; Luwor RB
    Sci Rep; 2020 Oct; 10(1):17768. PubMed ID: 33082482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma.
    Toth J; Egervari K; Klekner A; Bognar L; Szanto J; Nemes Z; Szollosi Z
    Pathol Oncol Res; 2009 Jun; 15(2):225-9. PubMed ID: 18752056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma.
    Liu X; Chen X; Shi L; Shan Q; Cao Q; Yue C; Li H; Li S; Wang J; Gao S; Niu M; Yu R
    J Exp Clin Cancer Res; 2019 May; 38(1):219. PubMed ID: 31122294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
    Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
    Taylor TE; Furnari FB; Cavenee WK
    Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.
    Yin D; Ogawa S; Kawamata N; Leiter A; Ham M; Li D; Doan NB; Said JW; Black KL; Phillip Koeffler H
    Oncogene; 2013 Feb; 32(9):1155-63. PubMed ID: 22580610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
    Lassman AB; Pugh SL; Wang TJC; Aldape K; Gan HK; Preusser M; Vogelbaum MA; Sulman EP; Won M; Zhang P; Moazami G; Macsai MS; Gilbert MR; Bain EE; Blot V; Ansell PJ; Samanta S; Kundu MG; Armstrong TS; Wefel JS; Seidel C; de Vos FY; Hsu S; Cardona AF; Lombardi G; Bentsion D; Peterson RA; Gedye C; Bourg V; Wick A; Curran WJ; Mehta MP
    Neuro Oncol; 2023 Feb; 25(2):339-350. PubMed ID: 35849035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
    Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
    Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
    Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
    J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amplification and overexpression of epidermal growth factor receptor gene in glioblastomas of Chinese patients correlates with patient's age but not with tumor's clinicopathological pathway.
    Xie D; Zeng YX; Wang HJ; Tai LS; Wen JM; Tao Y; Ma NF; Hu L; Sham JS; Guan XY
    Acta Neuropathol; 2005 Nov; 110(5):481-9. PubMed ID: 16151725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma.
    Loriguet L; Morisse MC; Dremaux J; Collet L; Attencourt C; Coutte A; Boone M; Sevestre H; Galmiche A; Gubler B; Chauffert B; Trudel S
    BMC Cancer; 2018 Oct; 18(1):964. PubMed ID: 30305059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
    Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
    EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells.
    Pellecchia S; De Martino M; Esposito F; Quintavalle C; Fusco A; Pallante P
    Cell Cycle; 2021 Apr; 20(7):716-729. PubMed ID: 33734003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
    Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL
    J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.